From Cutaneous Microbiota to Clinical Trial Recruitment... Diversity Matters
Dr. Zoe Draelos
Unless you have been under a pile of retention hyperkeratosis, it would be hard to say one has not heard the call to purposefully diversify clinical trial programs to ensure data generated is truly generalizable, let alone better appreciate demographic based nuances of disease presentation. Now how much is that happening in the OTC space you ask? Well, Dr. Zoe Draelos, former AAD V.P. and Clinical Trial G.O.A.T., will answer. Press play to pick apart how clinical studies evaluating over the counter products should be structured and rewind/listen twice for good luck to learn how to purposefully recruit a diverse group of subjects and tools to make it a reality. Best practices for picking clinically relevant and meaningful outcomes – check. Can a study evaluating a cleanser and moisturizer reveal new learnings and consideration? You betcha.
This podcast is funded by La Roche-Posay.
Listen Now
HOST: Adam Friedman, MD, FAAD
GUEST: Dr. Zoe Draelos
You May Also Like
Guest: Dr. Joseph Bax Corticosteroid injections are everywhere in musculoskeletal medicine. Epidurals, joints, facets, bursae: when inflammation and pain are the targets, steroids have long been one of the sharpest…
Guest: Dr. Tae Oh For too long, the therapeutic ladder in hidradenitis suppurativa has often looked less like a ladder and more like an uneven mound: try this, fail that,…
Get More from the JDD Podcast
Get the latest dermatology news delivered straight to your Inbox – sign up for the JDD Newsletter.
Discover the latest research, exclusive articles from leading dermatology experts,popular Podcast episodes, free CME activities, and more!
Subscribe
Podcast: Play in new window | Download
Subscribe: RSS








